Next Generation Longevity 2026 will convene in Osaka on 15–16 October at Nakanoshima Qross, Japan's government-backed regenerative medicine hub, gathering clinicians, researchers, founders and investors around precision medicine, biomarkers, applied AI and regenerative therapeutics. The meeting is structured as a small, curated format of debates, workshops and case-based Boardroom sessions rather than keynote lectures, with clinical and commercial implementation as the stated endpoint. Its premise is that longevity medicine's constraint is no longer knowledge generation but the translation of that knowledge into practice.
Key Points
- Inaugural NGL 2026 convenes in Osaka, 15–16 October
- Boardroom format pressure-tests assumptions instead of producing consensus
- Focus shifts from healthspan evidence to clinical implementation
Longevity Analysis
The gap between what longevity science supports and what clinicians can responsibly act on remains the field's central bottleneck, and forums that place evidence, practice and economics in the same room address it more directly than another round of data presentation. Regenerative therapeutics in particular depend on this translation step, where laboratory capability must meet reimbursement, regulation and patient-level decision-making. The choice of Japan is instructive: a population where daily habits already sustain exceptional healthspan offers a reminder that consistent practice, not novel intervention alone, produces durable outcomes.
Original published by Longevity.Technology, by Eleanor Garth.